Salute e Benessere

ONWARD Medical Receives FDA De Novo Classification and US Market Authorization…

THIS PRESS RELEASE CONTAINS INSIDE INFORMATION WITHIN THE MEANING OF ARTICLE (7)(1) OF THE EUROPEAN MARKET ABUSE REGULATION (596/2014) ARC-EX System is the first and only FDA approved technology shown to improve hand strength and sensation after chronic spinal cord injuryARC-EX System is an FDA Breakthrough Device and 2024 TIME Magazine Best Invention EINDHOVEN, the Netherlands, Dec.19, 2024(GLOBE NEWSWIRE) -- ONWARD Medical N.V. (Euronext: ONWD), the medical technology company...
Nasdaq GlobeNewswire
19/12/2024

Smoke Evacuation Systems Market to Hit US$ 266.4 Million by 2029 with 7.3% CAGR…

Browse in-depth TOC on "Smoke Evacuation Systems Market" Browse in-depth TOC on "Smoke Evacuation Systems Market" 455 - Tables56 - Figures401 - Pages Based on product,the smoke evacuation pencil and wand are the largest share in smoke evacuation system market because they serve a very important function of capturing surgical smoke right at the origin from an undiscerned source during electrosurgical and laser-based procedures. Such devices get used with surgical...
PR Newswire
19/12/2024

Cancer Vaccines Market to Hit USD 20.47 Billion by 2032 with 8.6% CAGR |…

Browse in-depth TOC on "Cancer Vaccines Market" Browse in-depth TOC on "Cancer Vaccines Market" 261 - Tables 37 - Figures 439 - Pages The 'type' segment is segmented into preventive and therapeutic vaccines (Neoantigen cancer vaccines and other cancer vaccines). The preventive vaccines segment dominated the market in 2023. The dominance is attributable to the widespread adoption of HPV vaccines (e.g., Gardasil, Cervarix) to prevent cervical cancer and Hepatitis B vaccines…
PR Newswire
19/12/2024

Artificial Intelligence in Healthcare Market to Hit US$ 164.16 Billion by 2030…

Browse in-depth TOC on "Artificial Intelligence in Healthcare Market"455 - Tables54 - Figures386 - Pages Browse in-depth TOC on "Artificial Intelligence in Healthcare Market" 455 - Tables 54 - Figures 386 - Pages The global Artificial Intelligence (AI) in healthcare market is segmented into integrated solutions, niche/point solutions, AI technology, and services, by offering. The integrated solutions segment is accounted for the largest share in 2023. The large share of…
PR Newswire
19/12/2024

GenBio AI Releases Phase 1 of World's First Digital Organism to Transform…

Unlike earlier models that focus on specific aspects of a multi-cellular organism, GenBio AI takes a holistic approach where multiscale foundation models are built in modules and integrated into a single system. These State-Of-The-Art models are unprecedented in their capabilities: Unlike earlier models that focus on specific aspects of a multi-cellular organism, GenBio AI takes a holistic approach where multiscale foundation models are built in modules and integrated into a single system...
PR Newswire
19/12/2024

Interventional Cardiology Devices Market to Hit US$ 37.27 Billion by 2029 with…

Browse in-depth TOC on "Interventional Cardiology Devices Market" Browse in-depth TOC on "Interventional Cardiology Devices Market" 379 - Tables 62 - Figures 367 - Pages Based on Angioplasty stent type,the interventional cardiology devices market has been segmented into drug-eluting stents, bare-metal stents & bioabsorbable stents. Drug-eluting stents (DES) offer several advantages in cardiovascular procedures compared to bare metal stents (BMS). One of the primary...
PR Newswire
19/12/2024

Eurobio Scientific: EB Development obtains a significant majority of the capital…

Eurobio Scientific: EB Development obtains a significant majority of the capital with 88.9% held at the end of the Reopened Offer to continue its development with NextStage AM and IK PartnersParis, 19 December 2024 - 10.30amEurobio Scientific(FR0013240934, ALERS, PEA-PME eligible) andEB Developmentannounce the final outcome of the takeover bid initiated by EB Development (the " Offer "), based on the results published on 18 December by the Autorité des marchés financiers (AMF)...
Nasdaq GlobeNewswire
19/12/2024

Telix Manufacturing Solutions, Brussels South Update: Cyclotron Installation…

Telix was granted an updated radiation licence in 2022 by the Belgian Federal Agency for Nuclear Control (FANC) for a broad range of commercially important medical isotopes[3]. Both cyclotrons have multi-isotope capacity and will have ARTMS' QUANTM Irradiation System™ (QIS™) installed to support high efficiency, large-scale and cost-effective production. This includes clinical and commercial supply in Europe of gallium-68 (68Ga), zirconium-89 (89Zr), fluorine-18 (18F) and copper-64 (64Cu), along…
PR Newswire
19/12/2024

Ultimovacs ASA: Notice of extraordinary general meeting on 9 January 2024 -…

Oslo, 19 December 2024: Reference is made to the stock exchange notice published by Ultimovacs ASA (the "Company") on 17 December 2024 regarding the contemplated business combination between the Company and Zelluna Immunotherapy AS and the fully committed private placement and the stock exchange notice published at 07:00 CET today.In today's notice, one attachment was missing. All documents are included in this announcement, The Company's board of directors (the "Board")…
Nasdaq GlobeNewswire
19/12/2024

HISENSE UNVEILS NEWEST SMART HOME AND AI INNOVATIONS AT CES 2025

Smart Kitchen Smart Kitchen Hisense's ConnectLife platform brings intelligent cooking features to your kitchen. Dish Designer, developed in collaboration with Microsoft using Azure AI Studio, is an AI-powered recipe assistant that suggests personalised recipes based on available ingredients, dietary restrictions, and preferences. The ConnectLife Meal Planner combines smart automation with family collaboration. It allows families to plan their weekly meals efficiently with AI-powered...
PR Newswire
19/12/2024

TargED Biopharmaceuticals doses first participant in Phase 1 clinical trial of…

The first study participant was successfully dosed yesterday [Dec 18] at a Phase 1 clinic in Germany. The study's design is a randomized, double-blind, placebo-controlled single-ascending dose study to evaluate TGD001's safety, tolerability and pharmacokinetics in healthy volunteers (EU CT ID number: 2024-514931-63-00). The first study participant was successfully dosed yesterday [ Dec 18 ] at a Phase 1 clinic inGermany. The study's design is a randomized, double-blind, placebo-controlled...
PR Newswire
19/12/2024

Implantica strengthens the strategic RefluxStop™ expansion with the addition of…

Prof. Dr. med. Frank Benedix, says, "I am very excited to be able to offer my patients the latest innovative technology in the surgical treatment of GERD, which has already helped several hundreds of patients in Germany and over 1000 patients across Europe. RefluxStop's long-term outcomes look very promising and offer access to an additional surgical option for previously untreatable patients and countless more GERD patients who struggle with the relentless and painful symptoms of the…
PR Newswire
19/12/2024

Ottimo Pharma Raises over $140 Million in Series A Financing

Simultaneously, Ottimo has expanded its management team under the leadership of David Epstein, Chair and Chief Executive Officer. The Company announces the appointment of Rick Anderson as SVP Finance, Spencer Fisk as Chief Technical and Quality Officer, and Ling Zeng as General Counsel and EVP of Execution. Rick, Spencer, and Ling bring extensive pharma experience, having held senior roles at Seagen, Novartis, and Dicerna Pharmaceuticals. Simultaneously, Ottimo has expanded its management…
PR Newswire
19/12/2024

French antitrust proceedings concluded

For further information, please contact Electrolux Press Hotline, +46 8 657 65 07. For further information, please contact Electrolux Press Hotline, +46 8 657 65 07. This information was brought to you by Cisionhttp://news.cision.com https://news.cision.com/electrolux-group/r/french-antitrust-proceedings-concluded,c4084732 The following files are available for download: View original content:...
PR Newswire
19/12/2024

Considering delayed non-dilutive sources of financing, CARBIOS postpones…

Considering delayed non-dilutive sources of financing, CARBIOS postpones construction of its Longlaville PET biorecycling plant for 6 to 9 months CARBIOS maintains a robust available cash position of 112 million euros on 30 November 2024CARBIOS confirms major advances in commercial contract negotiations and makes changes to its GovernanceCARBIOS is speeding up its discussions with public stakeholders and private investors. The subsidies obtained under the France 2030 bid operated...
Nasdaq GlobeNewswire
19/12/2024

Valneva Successfully Expands Access to Asia for its Chikungunya Vaccine with…

Saint-Herblain (France), Pune, (India), December 19, 2024–Valneva SE(“Valneva” or “the Company”), a specialty vaccine company, and Serum Institute of India (SII), the world's largest manufacturer of vaccines by number of doses, today announced an exclusive license agreement for Valneva's single-shot chikungunya vaccine that enables supply of the vaccine in Asia. The collaboration to support broader access to the vaccine in low-and-middle-income countries (LMICs) in the region falls...
Nasdaq GlobeNewswire
19/12/2024

EssilorLuxottica: Prada Group and EssilorLuxottica announce ten-years licensing…

Prada Group and EssilorLuxottica announce ten-years licensing renewalThe renewal is a testament to the strong confidence, trust and collaboration between the two companies Milan, Italy and Paris, France (19 December 2024 – 08:00 am CET) – Prada Group and EssilorLuxottica announce today the renewal of their licensing agreement for the development, production and worldwide distribution of eyewear under the Prada, Prada Linea Rossa and Miu Miu brands.The existing agreement, expiring...
Nasdaq GlobeNewswire
19/12/2024

AGM Statement

DXS INTERNATIONAL PLC (AQSE: DXSP)DXS AGM 2024 Statement The Board of DXS International plc (“the Company” or “DXSP”), the AQSE Growth Market quoted healthcare information and digital clinical decision support systems provider, is pleased to publish an update on operations and pipeline progress ahead of its Annual General Meeting (" AGM ") taking place today at Noon at Elm House, Tanshire Park, Shackleford Road. Elstead, Surrey GU8 6LB. During the AGM, the Company's CEO, David...
Nasdaq GlobeNewswire
19/12/2024

BioArctic announces global license agreement with Bristol Myers Squibb for…

BioArctic's PyroGlu-Aβ antibody program consists of novel antibodies targeting a specific truncated, pyroglutamate modified form of amyloid-beta. Monomers of PyroGlu-Aβ are highly prone to aggregate, leading to the formation of harmful aggregates which cause debilitating cognitive and other symptoms in Alzheimer's disease. BioArctic's PyroGlu-Aβ antibody program consists of novel antibodies targeting a specific truncated, pyroglutamate modified form of amyloid-beta. Monomers of PyroGlu-Aβ are...
PR Newswire
19/12/2024

Crossject confirms ZEPIZURE® supply chain readiness with another successful ISO…

Crossject successfully passes another ISO 13485 audit for sites in Dijon and Gray (France)Company is ramping up supply chain to prepare for commercialization in U.S.Dijon, France, December 19, 2024, 07:30 CET --Crossject (ISIN: FR0011716265; Euronext: ALCJ), a specialty pharma company preparing to commercialize its epilepsy rescue therapy ZEPIZURE®, has successfully concluded a surveillance audit of its manufacturing sites, delivering new evidence its supply chain is ready to move...
Nasdaq GlobeNewswire
19/12/2024

Ultimovacs ASA: Notice of extraordinary general meeting on 9 January 2024

Oslo, 19 December 2024: Reference is made to the stock exchange notice published by Ultimovacs ASA (the "Company") on 17 December 2024 regarding the contemplated business combination between the Company and Zelluna Immunotherapy AS and the fully committed private placement. The Company's board of directors (the "Board") hereby calls for an extraordinary general meeting on 9 January 2025 at 09:00 CET (the "EGM") to resolve upon the matters proposed by the Board in…
Nasdaq GlobeNewswire
19/12/2024

Roche's Phase IIb study of prasinezumab missed primary endpoint, but suggests…

PADOVA study showed numerical delay in motor progression and positive trends on multiple secondary and exploratory endpointsPrasinezumab continues to be well tolerated and no new safety signals were observed Roche is further evaluating the data and will work together with health authorities to determine next steps Basel, 19 December 2024 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today results from the Phase IIb PADOVA study investigating prasinezumab in 586 people with...
Nasdaq GlobeNewswire
19/12/2024

NMD Pharma Announces Publication of Phase 1 Clinical Trial Data Evaluating…

Aarhus, Denmark, 19 December 2024– NMD Pharma A/S, a clinical-stage biotech company dedicated to developing novel and improved treatments for patients living with neuromuscular diseases, today announced that findings from its Phase 1 trial evaluating the safety, pharmacokinetic (PK) and pharmacodynamic (PD) profile of NMD670 in healthy volunteers were published in the peer-reviewed journalClinical Pharmacology & Therapeutics. NMD670 is a novel, oral, small molecule inhibitor of the...
Nasdaq GlobeNewswire
19/12/2024

BIOVAXYS ANNOUNCES CLOSING OF SECOND TRANCHE OF PRIVATE PLACEMENT

Each Unit consist of one (1) common share in the capital of the Company (each, a "Share") and one (1) whole Share purchase warrant (each, a "Warrant"), whereby each Warrant is convertible into one additional Share at an exercise price of $0.15 until December 18, 2026, being the date that is 24 months from the date of issue. Each Unit consist of one (1) common share in the capital of the Company (each, a " Share ") and one (1) whole Share purchase warrant (each, a…
PR Newswire
19/12/2024
Altri  Comunicati